Research Topics
| N V NaoumovSummaryAffiliation: University College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Assessment and management of chronic hepatitis BNikolai V Naoumov
Institute of Hepatology, University College London, UCL Hospitals
Clin Med 2:306-10. 2002- Presence of a newly described human DNA virus (TTV) in patients with liver diseaseN V Naoumov
Institute of Hepatology, Department of Medicine, University College London Medical School, UK
Lancet 352:195-7. 1998..We investigated the presence of this virus in patients with liver disease in the UK to find out whether TTV infection is associated with liver damage... - Hepatitis C virus infection in Eastern EuropeN V Naoumov
Institute of Hepatology, University College London, England
J Hepatol 31:84-7. 1999..These will have a major role for adequate selection and monitoring of the patients' treatment... - Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantationN V Naoumov
Institute of Hepatology, University College London and UCL Hospitals, UK
J Hepatol 34:888-94. 2001..In a randomized trial we investigated a regimen where the initially given hepatitis B immunoglobulin (HBIg) is replaced by long-term lamivudine treatment... - Differentiation of core gene products of the hepatitis B virus in infected liver tissue using monoclonal antibodiesN V Naoumov
Institute of Hepatology, University College London Medical School, UK
J Med Virol 53:127-38. 1997.... - Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytesD Suri
Institute of Hepatology, University College London, 69-75 Chenies Mews, WC1E 6HX, London, UK
J Hepatol 35:790-7. 2001..CONCLUSIONS: These results provide direct evidence that IFN-gamma can inhibit both HBV transcription and replication in human hepatocytes without cell lysis... - Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre studyS Caronia
Department of Medicine, St Mary's Hospital ICSM, London, UK
J Hepatol 35:512-6. 2001..05) while the sustained response was 18 and 15%, respectively. CONCLUSIONS: Combination therapy with interferon plus amantadine does not lead to a significant increase in sustained response rates when compared to interferon monotherapy... 
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirinK H Tang
Institute of Hepatology, University College London, London, UK
Aliment Pharmacol Ther 27:810-9. 2008..Individualized treatment regimens, taking into account the heterogeneity of patients with chronic hepatitis C, are needed to improve treatment outcomes...
Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapyChee-Kin Hui
Department of Medicine, University of Hong Kong, Hong Kong, SAR, China
J Clin Microbiol 44:2983-7. 2006..The results of the RealART and Digene Hybrid assays were related (r = 0.94; P < 0.001) and diverged by 2 orders of magnitude. The RealART assay can be used to effectively monitor serum hepatitis B virus DNA levels...- Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg lossR Bridget Ferns
Centre for Virology, Department of Infection, University College, Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom
J Clin Virol 39:199-204. 2007..In patients with chronic hepatitis B virus (HBV) infection DNA levels do not always fall after anti-hepatitis B e (anti-HBe) seroconversion... - Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearanceJinlin Hou
Institute of Hepatology, University College London, London WC1E 6HX, UK
J Med Virol 79:1055-63. 2007..The optimal duration of interferon-based therapies in chronic hepatitis B may vary between different HBV genotypes... - Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis BGeorge K K Lau
Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China
Antivir Ther 12:705-18. 2007..The patterns of hepatitis B viral dynamics during different antiviral therapies and the associated changes in HBV-specific T-cell reactivity are not well defined... - Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivityHelen Cooksley
Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, United Kingdom
Antimicrob Agents Chemother 52:312-20. 2008..In conclusion, T-cell reactivity to HBV increases in a proportion of ADV-treated patients and is associated with greater suppression of HBV replication and HBeAg loss... - Telbivudine versus lamivudine in patients with chronic hepatitis BChing Lung Lai
University Department of Medicine, Queen Mary Hospital, Hong Kong, China
N Engl J Med 357:2576-88. 2007..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B... - APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replicationSandra Proto
Institute of Hepatology, University College London, and MRC Clinical Sciences Centre, Hammersmith Hospital, London WC1E 6HX, UK
Antiviral Res 78:260-7. 2008..We investigated the role of IFN-gamma-inducible nitric oxide synthase (iNOS) and APOBEC3 (A3) enzyme family in the inhibition of HBV replication by IFN-gamma... - Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapySamreen Ijaz
Virus Reference Department, Centre for Infections, Health Protection Agency, London, United Kingdom
J Med Virol 80:1160-70. 2008..The use of techniques such as Pyrosequencing provides an evidence-based approach for successful management of drug-resistant HBV... - Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo
Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Clin Gastroenterol Hepatol 4:233-48. 2006..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature... - Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype EKei Fujiwara
Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho, Nagoya 467 8601, Japan
J Virol 79:14404-10. 2005..This novel mutation may be specific to HBV genotype E, and its prevalence requires further investigation... - Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activityEirini I Rigopoulou
Institute of Hepatology, Division of Medicine, University College London, London, UK
Hepatology 42:1028-36. 2005..However, IL-12 does not abolish HBV replication in HBeAg-positive patients and does not maintain inhibition of HBV replication after lamivudine withdrawal... - Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigenGeorge K K Lau
Institute of Hepatology, University College London, London, England
Gastroenterology 122:614-24. 2002..Therapeutic immunization with HBV core gene or protein deserves further investigation in patients with chronic hepatitis B... - Translation of immunological knowledge into better treatments of chronic hepatitis BAntonio Bertoletti
Institute of Hepatology, University College of London, London, UK
J Hepatol 39:115-24. 2003 - Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivityFrancesco Torre
Institute of Hepatology, University College London, London, United Kingdom
J Med Virol 72:370-6. 2004.... - Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversionAlexander Evans
Institute of Hepatology, University College London, London, United Kingdom
Hepatology 48:759-69. 2008..Treatment-induced suppression of HBV replication reduces PD-1 expression; however, additional immunotherapeutic interventions are needed for restoration of T-cell functions... - A new intertype recombinant between genotypes C and D of hepatitis B virus identified in ChinaZhanhui Wang
College of Life Science, Wuhan University, Wuhan, China
J Gen Virol 86:985-90. 2005..Hybrids of different HBV genotypes might exhibit specific virological properties and their significance in the diagnosis and management of chronic hepatitis B deserves further investigation... - Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapyKwok H Tang
Institute of Hepatology, University College London, 69-75 Chenies Mews, London. WC1E 6HX, UK
J Hepatol 43:776-82. 2005..Enhancement of antiviral T-cell reactivity requires rapid viraemia clearance, rather than immunostimulation alone... - The potential of RNA interference as a tool in the management of viral hepatitisJohn A Taylor
School of Biological Sciences, University of Auckland, Auckland, New Zealand
J Hepatol 42:139-44. 2005 - Immunological techniques in viral hepatitisBarbara Rehermann
Immunology Section, Liver Diseases Branch NIDDK, National Institutes of Health, DHHS, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
J Hepatol 46:508-20. 2007..Our aim is to highlight topics and issues that were supported by general agreement and those that were controversial, as well as to provide suggestions for future work... - Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirinFrancesca Dal Pero
Venetian Institute for Molecular Medicine, Padova, 35129, Italy
J Infect Dis 196:998-1005. 2007..Little is known about NS5A sequences of HCV-1a. We investigated whether genetic variability of HCV-1a NS5A correlates with the early HCV kinetics during treatment... - Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virusEirini I Rigopoulou
Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, UK
Antiviral Res 75:36-42. 2007..Here we investigated whether ribavirin directly affects HCV-specific reactivity of CD4+T-lymphocytes from patients with CH-C... - Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virionsRalf Schilling
Institute of Hepatology, Department of Medicine, University College London, London WC1E 6HX, United Kingdom
J Virol 77:8882-92. 2003..These results suggest that HBs-specific IgG binds to hepatocytes and interacts with HBsAg within the cells. This may be relevant for the selection of surface antibody escape mutations... - SEN viruses and treatment response in chronic hepatitis C virusNikolai V Naoumov
Lancet 359:1779-80; author reply 1780. 2002 - Individualization of antiviral treatment regimens for chronic hepatitis CEmma Paulon
Institute of Hepatology, University College London, London, UK
Eur J Gastroenterol Hepatol 18:321-5. 2006..Accumulating evidence demonstrates that individualized treatment regimens, according to the timing of treatment-induced viral clearance, provide a safe and cost-effective approach, as well as an improvement in treatment efficacy... - In vitro analysis of hepatitis B virus specific CD4+ T cellsShilpa Chokshi
Institute of Hepatology, University College London, UK
Methods Mol Med 96:97-109. 2004